Dihematoporphyrin ether API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Dihematoporphyrin ether API 97067-70-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Dihematoporphyrin ether. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Dihematoporphyrin ether
- Synonyms:
- bis-1-(8-(1-hydroxyethyl)deuteroporphyrin-3-yl)ethyl ether , DHP ether , Dihematoporphyrin ether
- Cas Number:
- 97067-70-4
- DrugBank number:
- DB15351
- Unique Ingredient Identifier:
- 625J2HS54G
General Description:
Dihematoporphyrin ether, identified by CAS number 97067-70-4, is a notable compound with significant therapeutic applications. Dihematoporphyrin ether is under investigation in clinical trial NCT00118222 (High Light and Low Light Dose PDT in Glioma).
Categories:
Dihematoporphyrin ether is categorized under the following therapeutic classes: Antineoplastic Agents, Biological Factors, Dermatologicals, Hematoporphyrin Derivative, Hematoporphyrins, Heterocyclic Compounds, Fused-Ring, Photosensitizing Agents, Pigments, Biological, Porphyrins, Radiation-Sensitizing Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Dihematoporphyrin ether is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
